2020 has been a year like no other—full of unprecedented challenges for everyone. As we welcome in 2021, I want to reflect on what we’ve accomplished throughout the year and offer my thanks to the Genome Medical team and our incredible partners who collaborate with us to bring genomics to more patients all around the country.
A look at 2020, by the numbers:
90 Million: lives covered, which means 25% of the U.S. population can come to Genome Medical and have our genetic services covered as part of their in-network care.
$14 Million: additional capital raised, led by a new investor, Samsung Catalyst Fund, with support from our incredible long-term investors.
88: Employees at Genome Medical at the close of 2020
60+: The size of our clinical team, including full-time and network genetic counselors, medical geneticists and other MDs, pharmacists and clinical care support.
50: States where Genome Medical is licensed as a medical practice
40: New employees we hired in 2020 -- most of whom were recruited, hired, onboarded and trained virtually
30+: New programs launched in 2020, with major health systems, hospitals and other partners.
2: New product lines brought to market with the introduction of technology services and strategic advisory services to support the design, development and implementation of precision medicine programs.
And a number of awards and recognitions, including the Tom Main Health Innovation Mentorship Award, in recognition of our pursuit of health transformation; the Frost and Sullivan breakout innovator award; and CB Insights Digital Health 150 recognizing the most innovative digital health startups.
I am so proud of our team, our network of care givers, our investors, advisors, partners and supporters. Thank you for making 2020 a transformative year.
Our Vision for 2021
Looking ahead, the latest wave of COVID will impact health care in ways we remain quite concerned about. Even with the advances we’ve achieved, the barrier now is that the vast majority of patients who could benefit from genetic care are not being identified as part of their primary and even specialty care. Patients have deferred routine medical care, including cancer screenings, which means we are not identifying and finding cancers early. We will now be diagnosing cancer at a later stage, and that will tax the health care system. One study found that the rate of cancer diagnosis was down 74% from April 2019 to April 2020. 
That’s part of the reason we invested so heavily in 2020 in the development of Genome Care NavigatorTM as a 100% virtual solution for patient engagement, assessment and care navigation. We will be able to accelerate the identification of those at elevated risk for cancer and provide information that empowers the individual to seek medical care and seek it early.
For 2021, population impact will be a core theme. We will be working extensively with health systems on population genomics, and want to impact more patients through our strategic advisory services. First introduced in early 2020, this is a growing, hands-on approach to bringing forward precision medicine and leading the design and delivery of customized programs. We want to expand the reach of technology tools and platforms to support non-genetics professionals in identifying which patients need genetics. It’s core to fostering the adoption of genetic care in clinical settings.
What motivates me, always, is the need to impact patients’ lives. Genomics has profound impact and profound potential for precision medicine. We need to bring it to patients today.
This has been our driving force during 2020, and we are proud to have helped so many patients throughout this most difficult year. We are now looking forward to bringing the benefits of genomic medicine to ever-growing numbers of people in 2021. Cheers to the New Year!